Volume 22, Issue 5 pp. 1363-1367
Original Article
Free Access

An outbreak of hepatitis A among south african patients with hemophilia: Evidence implicating contaminated factor VIII concentrate as the source

Mary-Anne Kedda

Mary-Anne Kedda

Medical Research Council/Witwafersrand University Molecular Hepatology Research Unit, Department of Medicine, University of the Witwatersrand, Johannesburg

Search for more papers by this author
Michael C. Kew MD,DSc,FRCP

Corresponding Author

Michael C. Kew MD,DSc,FRCP

Medical Research Council/Witwafersrand University Molecular Hepatology Research Unit, Department of Medicine, University of the Witwatersrand, Johannesburg

Department of Medicine, Medical School, 7 York Rd, Parktown 2193, Johannesburg, South Africa===Search for more papers by this author
Richard J. Cohn

Richard J. Cohn

Hemophilia Clinic, Johannesburg Hospital, Johannesburg

Search for more papers by this author
Stephen P. Field

Stephen P. Field

Hemophilia Clinic, Johannesburg Hospital, Johannesburg

Search for more papers by this author
Rosemary Schwyzer

Rosemary Schwyzer

Natal Blood Transfusion Service, Durban, South Africa

Search for more papers by this author
Ernest Song

Ernest Song

Natal Blood Transfusion Service, Durban, South Africa

Search for more papers by this author
F. Fernandes-Costa

F. Fernandes-Costa

Natal Blood Transfusion Service, Durban, South Africa

Search for more papers by this author
First published: November 1995
Citations: 38

Abstract

We report an outbreak of hepatitis A in nine South African hemophiliacs treated exclusively with infusions of factor VIII concentrate. The solvent/detergent (S/D) method (which does not inactivate nonenveloped viruses) was used for virus eradication. In three of six patients studied at a molecular level hepatitis A virus (HAV) complementary DNA (cDNA) amplified from serum by reverse transcription-polymerase chain reaction (RT-PCR) was identical to HAV cDNA in 1 of 14 lots (no. 53) of factor VIII tested. The plasma for lot 53 was obtained from donors in the United States: 1 of 12 samples of this source material contained the same HAV cDNA sequences. In another two patients receiving lot 53, the degree of identity between HAV cDNA in serum and that in factor VIII was only 88% and 89%, respectively, and in the sixth patient, who did not receive lot 53, it was 90%. The degree of HAV cDNA homology among five patients in an independent point-source outbreak of hepatitis A was 100%, and that in nine patients who acquired this infection sporadically in Johannesburg, Egypt, or Russia, was 93% to 100%. Whether the three hemophiliacs with low HAV cDNA homology with lot 53 acquired the infection from other unidentified virus strains contaminating factor VIII or from extraneous sources is unknown. This study provides further evidence that factor VIII concentrate prepared by the S/D method may be contaminated by the HAV, in this instance at source, and may cause hepatitis in recipients. Proof of a cause-and-effect relationship will, however, depend on animal inoculation studies. (Hepatology 1995; 22:1363-1367).

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.